radiation oncologist, innovator, clinical trialist, father, GI oncology @WashURadOnc
St Louis, MO
Joined October 2018
- Tweets847
- Following332
- Followers1.1K
- Likes3.4K
Hyun Kim retweeted
🚨 Could radioligand therapy be moving into the frontline setting for metastatic hormone-sensitive prostate cancer?
Article 📰
thelancet.com/journals/lance…
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
The phase 3 PSMAddition trial showed that adding ^177Lu-PSMA-617 to standard androgen deprivation therapy (ADT) 💊 plus an androgen receptor pathway inhibitor (ARPI) significantly 📈 improved radiographic progression-free survival in patients with PSMA-positive metastatic hormone-sensitive #ProstateCancer , reducing the risk of progression or death by 28%.
✅ Although adverse events, particularly dry mouth, cytopenias, and gastrointestinal effects, were more frequent, no unexpected safety concerns emerged, supporting this combination as a potential new frontline treatment.
@DrScottTagawa
@OJSartor
@mishabeltran
@shilpaonc
@cdanicas
@adapthyun
@DrNordquist
Thank you @NiuSanford ! Congrats to the @WashUMedRadOnc team for providing these additional data to guide treatment for this very challenging clinical scenario.
SBRT (50Gy/5fx, MR adaptive) in locally recurrent PDAC.
N=46 (7 w prior RT). 1 year LC 73%, median OS 19 mo.
Ablative RT = feasible, safe in locally recurrent setting & can confer long term dz control.
Great to see this data published - congrats @adapthyun & team! @OncoAlert
Hyun Kim retweeted
Great talk at #MRPTS26 on managing RPT emergencies by Dr. Hyun Kim @adapthyun with a call/need for RadOnc and RPT physicians to own toxicities related to the RPTs they prescribe/administer. @cityofhope
Hyun Kim retweeted
@adapthyun of @COH_RadOnc presenting on infusion troubleshooting and radiation safety challenges with RPT. @ASTRO_org #MRPTS26
Hyun Kim retweeted
What better way to catch up with my GI rad onc friends and colleagues than at a Disney-themed restaurant, sparkly cake and all ✨ 🍰#ACRO2026 @LeilaTchelebi @adapthyun @ldawsonmd
Hyun Kim retweeted
Gathering with friends and colleagues not only keeps us going, but accelerates progress by developing and strengthening collaborations. #radonc happy hour @ASCO #GI26 @NiuSanford @alexhotca @radoncbme @ldawsonmd @lauren_henke
Appreciate this fantastic opportunity! (Has been a minute since I signed onto twitter/x so sorry for the very delayed response). @COH_RadOnc and @TeWilliamsMD has been nothing short of stellar in their welcome.
We’re thrilled to welcome @adapthyun to @COH_RadOnc! Dr. Hyun Kim is an internationally-recognized thought leader in GI cancer, adaptive radiation therapy & radiopharmaceuticals, and will lead our GI RadOnc & #theranostics programs. #radonc @cityofhope @NRGonc @ASTRO_org
Hyun Kim retweeted
Our final speaker for the KOSRO-KASTRO session is Dr @jihyunRadOnc who will provide the latest evidence and advancements for treating refractory ventricular tachycardia. See you tomorrow 8am Room 314!
Thanks @MikeChuongMD @sueyom! It was a privilege to work under your leadership. @IJROBP
Now time to change my email address before the reviewer invites start coming in 😁
🤩 What a truly amazing group of human beings!!
So sorry to miss this as I was giving a talk at #ASTRO25
Excited to announce our new @IJROBP GI associate editors @LCUBLD @AitkenKatharine 🙌
Much gratitude to @adapthyun & Andrzej Wojcieszynski who are rotating off 🙏
Hyun Kim retweeted
NOM short course ! Locally advanced after TNT and 25-30 in 5 to tumor and 30-35 to sidewall nodes had a CCR had a 72 percent CCR rate 🔥
Boost to primary did not lead to better CCR - perhaps while we know there is a dose response (OPERA trial) for locally advanced disease modern systemic helps considerably. Need to see the results of the German AIO trial - congrats to @adapthyun and the whole team 👏🏼👏🏼
NOM-ERA (clinicaltrials.gov/study/NCT…) accrual and treatment complete! Look forward to data presented in 2025! @AnkerUVMRadOnc
Hyun Kim retweeted
NOM-ERA results just dropped! 🔥 #ASTRO25
Awesome work @adapthyun et al!
Wondering if those who got the optional 30 Gy × 5 primary tumor boost had larger tumors or more adverse features since cCR and TME-free survival looked similar overall.
sciencedirect.com/science/ar…
Patients deserve options, including shorter radiation courses. Agree 5-6 weeks of RT has best published rates of avoiding rectal cancer surgery so far, but all that time is hard on pts. NOM-ERA’s 1 wk of RT with boost was VERY popular with @UVMcancercenter pts. Eager for results!
Hyun Kim retweeted
Yup, I wouldn’t give up on SCRT so easily to go back to CRT without conclusive data. Keep going @adapthyun. I will also be excited to see what PULSAR with gross dz boost can do from @NiuSanford! Looking forward to seeing head to head of just 5x5 vs CRT.
Hyun Kim retweeted
And the plot thickens for short course RT in rectal cancer!
72% cCR & 57% 2-year TME free survival via 4 cycles FOLFOX/CAPOX --> 25-30Gy/5 fraction RT (short course with optional boost).
Congrats @adapthyun & looking forward to study details. #ASTRO25
NOM-ERA results just dropped! 🔥 #ASTRO25
Awesome work @adapthyun et al!
Wondering if those who got the optional 30 Gy × 5 primary tumor boost had larger tumors or more adverse features since cCR and TME-free survival looked similar overall.
sciencedirect.com/science/ar…
Hyun Kim retweeted
Congratulations to Stephanie Markovina, MD, PhD, a recipient of the 2025 Dean’s Impact Award! Her dedication to community-engaged leadership has created lasting impact across clinical care, #cervicalcancer research & mentoring trainees. Read more - bit.ly/42tSYtS
Hyun Kim retweeted
Read this new brief report from @adapthyun @WashUMedRadOnc et al on minimizing bowel gas artifact in CT-guided online adaptive radiotherapy with prolonged supine positioning in the #RedJournal: tinyurl.com/redhkim
Hyun Kim retweeted
Ablative RT for technically resectable (med inoperable) pancreas ca
In disease site w high rate distant mets, morbidity tradeoffs b/w local therapies must be considered
Small series, but ~early lung SBRT trials, potential for practice-changing paradigm
🤞future coop group RCT
Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resectable pancreatic cancer who could not undergo surgery.
ja.ma/4lxAyjx @EileenMOReilly @JohnCuaron
Hyun Kim retweeted
Thanks for this paper!
Not too long ago, treating pancreas tumors w duodenal invasion to 100 Gy (prescription dose)/5 fx would have been unfathomable.
On NRG GI-011/LAP100, we will encourage 5 over 25 fx regimen - this paper suggests 5 fractions should be feasible for most.
Congrats to @AldenDSouza3 @KylieKangMD for this work on MR guided adaptive SBRT for pancreatic tumors abutting/invading organs at risk in @IJROBP. Classic teaching is to prolong fractionation and avoid SBRT for OAR abutment/invasion due to toxicity. Still true in ART era? 1/
